No Easy Answers for Breast Cancer Gene Testing
|
By LabMedica International staff writers Posted on 18 Jan 2010 |
A genetic mutation can significantly increases a woman's risk of developing breast cancer and ovarian cancer. But does that mean everyone should be tested? A new direct-to-consumer advertising campaign in select markets in the United States urges women to be tested. However, some experts warn that the test is not appropriate for all women.
"While the test is a very easy thing to do--it's a simple blood test --the interpretation of the results can sometimes be very complicated,” said Mark Pearlman, M.D., vice chair and professor of obstetrics and gynecology at the University of Michigan (U-M) Medical School (Ann Arbor, USA).
In fact, experts estimate only 2% of the population should be tested for these mutations, which occur in BRCA1 or BRCA2 genes. Women who inherit a mutation in these genes face a higher lifetime risk of developing breast and ovarian cancer, and cancer is more likely to develop at an earlier age. Lifetime risk of breast cancer in these women jumps from 12.5% in the general population to approximately 60% in women with BRCA mutations. Lifetime ovarian cancer risk rises from 1.4% to 40% for those with the mutation.
But most breast and ovarian cancers are random, and are not linked to the BRCA genes. Fewer than 10% of all women with breast cancer carry one of the BRCA gene mutations, and about 15% of women with ovarian cancer carry one of the mutations. "It's very important that the right women seek out genetic testing for breast and ovarian cancer,” said Sofia Merajver, M.D., Ph.D., director of the Breast and Ovarian Risk Evaluation Program at the University of Michigan Comprehensive Cancer Center. "Cancer risk is more complex than a simple yes or no, and the test for genetic mutations is only part of the picture.”
Women who seek genetic testing should work with a genetic counselor and a physician who is specially trained to help people understand what their test results mean for their cancer risk--and what they can do to reduce that risk. "Working with a genetic counselor, somebody who understands genetics, is very important because a positive test has a plan that has to go with it. At the same time, a negative test doesn't always mean that person is no longer at risk. So getting the test results back without any other knowledge and without any other information is potentially dangerous,' Dr. Pearlman remarked.
Dr. Pearlman and Dr. Merajver work together at the U-M Comprehensive Cancer Center to manage women who are seeking or have undergone genetic testing for breast and ovarian cancer, educating women and their families through genetic counseling, and providing prevention, risk management, and coping strategies for women who test positive. "It's important to understand that getting the genetic test result is only a piece of the puzzle. It really takes a professional who understands genetics to help work with individual women and men to allow them to understand exactly what that piece of information means to them in terms of their risk, their loved ones' risks and what can then be done to help lower that risk,” Dr. Pearlman commented.
For women who do test positive for a mutation, Dr. Pearlman's clinic helps them decide what to do about it. Options include getting mammograms at a younger age or more frequently, using breast magnetic resonance imaging (MRI), taking medication to reduce risk, or making lifestyle changes. Women who are finished with childbearing typically have their ovaries removed, and women may also choose to have their breasts removed to limit their risk.
Doctors recommend genetic testing for those who have: high numbers of family members with cancer diagnoses throughout several generations, either maternal or paternal; family member diagnosed with cancer before age 50; family members who have been diagnosed with multiple cancers (for example, breast and ovarian); and male breast cancers, or clusters of other cancers such as colon, prostate, stomach, or pancreatic.
Related Links:
University of Michigan Medical School
"While the test is a very easy thing to do--it's a simple blood test --the interpretation of the results can sometimes be very complicated,” said Mark Pearlman, M.D., vice chair and professor of obstetrics and gynecology at the University of Michigan (U-M) Medical School (Ann Arbor, USA).
In fact, experts estimate only 2% of the population should be tested for these mutations, which occur in BRCA1 or BRCA2 genes. Women who inherit a mutation in these genes face a higher lifetime risk of developing breast and ovarian cancer, and cancer is more likely to develop at an earlier age. Lifetime risk of breast cancer in these women jumps from 12.5% in the general population to approximately 60% in women with BRCA mutations. Lifetime ovarian cancer risk rises from 1.4% to 40% for those with the mutation.
But most breast and ovarian cancers are random, and are not linked to the BRCA genes. Fewer than 10% of all women with breast cancer carry one of the BRCA gene mutations, and about 15% of women with ovarian cancer carry one of the mutations. "It's very important that the right women seek out genetic testing for breast and ovarian cancer,” said Sofia Merajver, M.D., Ph.D., director of the Breast and Ovarian Risk Evaluation Program at the University of Michigan Comprehensive Cancer Center. "Cancer risk is more complex than a simple yes or no, and the test for genetic mutations is only part of the picture.”
Women who seek genetic testing should work with a genetic counselor and a physician who is specially trained to help people understand what their test results mean for their cancer risk--and what they can do to reduce that risk. "Working with a genetic counselor, somebody who understands genetics, is very important because a positive test has a plan that has to go with it. At the same time, a negative test doesn't always mean that person is no longer at risk. So getting the test results back without any other knowledge and without any other information is potentially dangerous,' Dr. Pearlman remarked.
Dr. Pearlman and Dr. Merajver work together at the U-M Comprehensive Cancer Center to manage women who are seeking or have undergone genetic testing for breast and ovarian cancer, educating women and their families through genetic counseling, and providing prevention, risk management, and coping strategies for women who test positive. "It's important to understand that getting the genetic test result is only a piece of the puzzle. It really takes a professional who understands genetics to help work with individual women and men to allow them to understand exactly what that piece of information means to them in terms of their risk, their loved ones' risks and what can then be done to help lower that risk,” Dr. Pearlman commented.
For women who do test positive for a mutation, Dr. Pearlman's clinic helps them decide what to do about it. Options include getting mammograms at a younger age or more frequently, using breast magnetic resonance imaging (MRI), taking medication to reduce risk, or making lifestyle changes. Women who are finished with childbearing typically have their ovaries removed, and women may also choose to have their breasts removed to limit their risk.
Doctors recommend genetic testing for those who have: high numbers of family members with cancer diagnoses throughout several generations, either maternal or paternal; family member diagnosed with cancer before age 50; family members who have been diagnosed with multiple cancers (for example, breast and ovarian); and male breast cancers, or clusters of other cancers such as colon, prostate, stomach, or pancreatic.
Related Links:
University of Michigan Medical School
Latest Molecular Diagnostics News
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
- Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








